Human DEGS1 adenoviral particles

The DEGS1 gene (Delta(4)-desaturase, sphingolipid 1) encodes a key enzyme in the sphingolipid biosynthesis pathway that specifically catalyzes the conversion of dihydroceramide to ceramide. This step is essential for maintaining cellular sphingolipid homeostasis, which affects membrane integrity, signal transduction, and apoptosis. Dysregulation of the DEGS1 gene has been implicated in a variety of diseases, including neurodegenerative diseases, cancer, and metabolic syndrome. Its role in regulating ceramide levels makes it a potential therapeutic target, as ceramide is involved in cellular stress responses and proliferation.

Human DEGS1 adenoviral particles are engineered viral vectors designed to deliver the DEGS1 gene to target cells for overexpression studies. These particles utilize adenoviral technology, which allows for high transduction efficiencies in a variety of cell types, including primary and dividing cells. The adenoviral system ensures stable and transient gene expression, making it ideal for functional analyses, such as studying the role of DEGS1 in sphingolipid metabolism or its effects on disease models. These particles are typically replication-defective, which improves safety by preventing uncontrolled spread of the virus. They can be used for in vitro and in vivo applications, such as gene therapy research or the study of ceramide-related pathological mechanisms.